BioCardia Unveils Groundbreaking Results in Phase III CardiAMP Cell Therapy for Heart Failure
BioCardia, Inc., a leader in biotechnological advancements for cardiovascular diseases, recently announced remarkable interim results from its Phase III CardiAMP® Cell Therapy trial for treating advanced chronic heart failure. These findings mark a significant milestone in the pursuit of innovative treatments for heart failure, showcasing the potential of stem cell therapy to revolutionize patient care. […]
The Dawn of a New Era in Heart Failure Treatment: BioCardia’s CardiAMP Heart Failure II Phase 3 Pivotal Study
In an exciting development for the field of cardiovascular medicine, BioCardia, Inc., a pioneering biotechnology company, has announced the activation of the CardiAMP Heart Failure II Phase 3 pivotal study. This groundbreaking study, recently greenlit by the FDA, represents a significant leap forward in the treatment of ischemic heart failure through advanced cell therapy techniques. […]
BioCardia Announces FDA Approval for Groundbreaking Heart Failure Treatment
BioCardia, Inc., a prominent player in the development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has recently announced a significant milestone. The U.S. Food and Drug Administration (FDA) has approved the Phase III clinical trial protocol for BioCardia’s CardiAMP autologous cell therapy. This therapy is designed for patients suffering from ischemic heart […]
Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting
SUNNYVALE, Calif., March 06, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces that detailed echocardiography data from the roll-in cohort of the Phase III CardiAMP® Cell Therapy Heart Failure Trial is being presented today at the American College of Cardiology annual meeting by […]